🔎 Trials Near Me

Home › Atherosclerosis › Arizona › Tucson

Atherosclerosis clinical trials in Tucson, AZ

5 studies for Atherosclerosis are looking for participants at sites in and around Tucson (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

RecruitingPhase 2
  • Pima Heart, Tucson
  • Eclipse Clinical Research, Tucson
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07783802

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

RecruitingPhase 3
  • Pima Heart, Tucson
  • Eclipse Clinical Research, Tucson
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07157774

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

RecruitingPhase 2/3
  • AKDHC Medical, Tucson
  • Southern Arizona VA Health Care System, Tucson
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05485961

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

RecruitingPhase 3
  • Research Site, Tucson
  • Research Site, Tucson
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT07000357

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

RecruitingPhase 4
  • Southern Arizona VA Health Care System, Tucson, AZ, Tucson
Ages 18 and older · All sexes · Updated Dec 17, 2025 · NCT02915198

About Atherosclerosis

Atherosclerosis is hardening and narrowing of the arteries caused by the buildup of a fatty substance called plaque. Learn about the risks and prevention.

More about Atherosclerosis on MedlinePlus

Atherosclerosis trials in other cities

Other studies in Tucson

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.